

# Comparison of second-line hormonal agents medroxyprogesterone acetate and aminoglutethimide in advanced breast cancer

<b>Submission date</b> 19/08/2002	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
<b>Registration date</b> 19/08/2002	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
<b>Last Edited</b> 27/01/2015	<b>Condition category</b> Cancer	<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
--

**Contact details**  
UKCCCR Register Co-ordinator  
MRC Clinical Trials Unit  
222 Euston Road  
London  
United Kingdom  
NW1 2DA

## Additional identifiers

**Protocol serial number**  
BR3004

## Study information

**Scientific Title**  
Comparison of second-line hormonal agents medroxyprogesterone acetate and aminoglutethimide in advanced breast cancer

**Study objectives**

Not provided at time of registration.

**Ethics approval required**

Old ethics approval format

**Ethics approval(s)**

Not provided at time of registration.

**Study design**

Randomised controlled trial

**Primary study design**

Interventional

**Study type(s)**

Treatment

**Health condition(s) or problem(s) studied**

Breast cancer

**Interventions**

Patients are randomised to receive either:

1. Group A: Medroxyprogesterone acetate 250 mg four times daily until disease progression or failure of treatment.
2. Group B: Aminoglutethimide 250 mg twice daily plus hydrocortisone 20 mg twice daily until disease progression or failure of treatment. There is a crossover option on disease progression or failure of treatment.

**Intervention Type**

Drug

**Phase**

Not Applicable

**Drug/device/biological/vaccine name(s)**

Medroxyprogesterone acetate, aminoglutethimide, hydrocortisone

**Primary outcome(s)**

Not provided at time of registration.

**Key secondary outcome(s)**

Not provided at time of registration.

**Completion date**

01/08/1996

**Eligibility****Key inclusion criteria**

1. Advanced breast cancer
2. Relapsed or failed following tamoxifen treatment
3. Postmenopausal

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Not Specified

**Sex**

Not Specified

**Key exclusion criteria**

Not provided at time of registration

**Date of first enrolment**

01/08/1991

**Date of final enrolment**

01/08/1996

**Locations****Countries of recruitment**

United Kingdom

England

**Study participating centre**

UKCCCR Register Co-ordinator

London

United Kingdom

NW1 2DA

**Sponsor information****Organisation**

Ciba-Geigy Pharmaceuticals (Switzerland)

**ROR**

<https://ror.org/02f9zrr09>

## **Funder(s)**

### **Funder type**

Industry

### **Funder Name**

Ciba-Geigy Pharmaceuticals, Farmitalia Carlo Erba

## **Results and Publications**

### **Individual participant data (IPD) sharing plan**

#### **IPD sharing plan summary**

Not provided at time of registration